Zacks Investment Research Downgrades Nantkwest (NK) to Hold
Nantkwest (NASDAQ:NK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “
NK has been the subject of a number of other research reports. BidaskClub lowered Nantkwest from a “sell” rating to a “strong sell” rating in a report on Friday, September 22nd. Raymond James Financial reiterated a “hold” rating on shares of Nantkwest in a report on Monday, December 11th. Three analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. Nantkwest presently has a consensus rating of “Hold” and a consensus price target of $5.25.
Large investors have recently modified their holdings of the stock. Voya Investment Management LLC bought a new position in Nantkwest in the second quarter worth approximately $102,000. Gotham Asset Management LLC bought a new position in Nantkwest in the second quarter worth approximately $104,000. Nationwide Fund Advisors raised its stake in Nantkwest by 67.6% in the second quarter. Nationwide Fund Advisors now owns 17,302 shares of the biotechnology company’s stock worth $131,000 after buying an additional 6,977 shares in the last quarter. New York State Common Retirement Fund raised its stake in Nantkwest by 9.0% in the second quarter. New York State Common Retirement Fund now owns 19,400 shares of the biotechnology company’s stock worth $147,000 after buying an additional 1,599 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Nantkwest by 13.0% in the second quarter. Wells Fargo & Company MN now owns 20,914 shares of the biotechnology company’s stock worth $158,000 after buying an additional 2,400 shares in the last quarter. 19.11% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/16/zacks-investment-research-downgrades-nantkwest-nk-to-hold.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related stocks with our FREE daily email newsletter.